troglitazone has been researched along with Diabetes Mellitus, Type 1 in 15 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 7.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Thus, the prevention of autoimmune diabetes in NOD mice by TGZ seems to be associated with suppression of IL-1beta-induced ICAM-1 expression leading to a reduced vulnerability of pancreatic beta-cells during the effector stage of beta-cell destruction." | 5.32 | Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. ( Augstein, P; Berg, S; Dunger, A; Hehmke, B; Heinke, P; Salzsieder, E; Wachlin, G, 2003) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 5.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 3.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Troglitazone treatment of type 2 diabetic patients diminishes sCD40L levels, suggesting a novel antiinflammatory mechanism for limiting diabetes-associated arterial disease." | 2.71 | Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. ( Bernal, MR; Calle-Pascual, AL; Fernández-Cruz, A; Goldfine, A; Horton, E; Jarolim, P; Libby, P; Nuzzo, R; Schönbeck, U; Varo, JJ; Varo, N; Veves, A; Vicent, D, 2003) |
| "Thus, the prevention of autoimmune diabetes in NOD mice by TGZ seems to be associated with suppression of IL-1beta-induced ICAM-1 expression leading to a reduced vulnerability of pancreatic beta-cells during the effector stage of beta-cell destruction." | 1.32 | Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells. ( Augstein, P; Berg, S; Dunger, A; Hehmke, B; Heinke, P; Salzsieder, E; Wachlin, G, 2003) |
| "Troglitazone has been reported to be beneficial in a small group of patients with nonalcoholic steatohepatitis (NASH)." | 1.31 | Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. ( Angulo, P; Lindor, KD, 2001) |
| "Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles." | 1.31 | [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001) |
| "Troglitazone is a new oral antidiabetic agent and has been reported to reduce insulin resistance and improve peripheral hyperinsulinemia in patients with noninsulin-dependent diabetes mellitus." | 1.30 | Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats. ( Mitsuo, M; Nakai, I; Oka, T; Shimizu, Y; Uchiyama, K; Yasunami, Y, 1997) |
| "Troglitazone has recently been introduced in the treatment of Type 2 diabetes." | 1.30 | Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse. ( Batchelor, K; Beales, PE; Giorgini, AE; Liddi, R; Pozzilli, P; Procaccini, E; Signore, A, 1998) |
| "Troglitazone treatment with MLDSTZ injection prevented hyperglycemia (230 +/- 30 mg/dl) and, suppressed insulitis and TNF alpha production from intraperitoneal exudate cells." | 1.30 | Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice. ( Fujiwara, T; Fukushige, J; Horikoshi, H; Hosokawa, T; Izumi, T; Kurakata, S; Ogawa, J; Takahashi, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (53.33) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solignac, M | 1 |
| Augstein, P | 1 |
| Dunger, A | 1 |
| Heinke, P | 1 |
| Wachlin, G | 1 |
| Berg, S | 1 |
| Hehmke, B | 1 |
| Salzsieder, E | 1 |
| Varo, N | 1 |
| Vicent, D | 1 |
| Libby, P | 1 |
| Nuzzo, R | 1 |
| Calle-Pascual, AL | 1 |
| Bernal, MR | 1 |
| Fernández-Cruz, A | 1 |
| Veves, A | 1 |
| Jarolim, P | 1 |
| Varo, JJ | 1 |
| Goldfine, A | 1 |
| Horton, E | 1 |
| Schönbeck, U | 1 |
| Lindsey, C | 1 |
| Graham, M | 1 |
| McMurphy, J | 1 |
| Shimabukuro, M | 1 |
| Koyama, K | 1 |
| Lee, Y | 1 |
| Unger, RH | 1 |
| Uchiyama, K | 1 |
| Nakai, I | 1 |
| Shimizu, Y | 1 |
| Mitsuo, M | 1 |
| Yasunami, Y | 1 |
| Oka, T | 1 |
| Gitlin, N | 1 |
| Julie, NL | 1 |
| Spurr, CL | 1 |
| Lim, KN | 1 |
| Juarbe, HM | 1 |
| Beales, PE | 1 |
| Liddi, R | 1 |
| Giorgini, AE | 1 |
| Signore, A | 1 |
| Procaccini, E | 1 |
| Batchelor, K | 1 |
| Pozzilli, P | 1 |
| Park, MH | 1 |
| Pelegrin, D | 1 |
| Haug, MT | 1 |
| Young, JB | 1 |
| Yamakita, T | 1 |
| Ishii, T | 1 |
| Mori, T | 1 |
| Yoshioka, K | 1 |
| Sato, T | 1 |
| Tanaka, S | 1 |
| Kurimasa, H | 1 |
| Fujita, K | 1 |
| Fujii, S | 1 |
| Herrine, SK | 1 |
| Choudhary, C | 1 |
| Ogawa, J | 1 |
| Takahashi, S | 1 |
| Fujiwara, T | 1 |
| Fukushige, J | 1 |
| Hosokawa, T | 1 |
| Izumi, T | 1 |
| Kurakata, S | 1 |
| Horikoshi, H | 1 |
| Isshiki, K | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Kikkawa, R | 1 |
| Angulo, P | 1 |
| Lindor, KD | 1 |
| Demant, T | 1 |
1 review available for troglitazone and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[Kidney disease and insulin resistance--clinical impact of thiazolidinedione compounds for kidney disease].
Topics: Animals; Chromans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents | 2000 |
1 trial available for troglitazone and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.
Topics: Acute Disease; Adult; Aged; Arteriosclerosis; Body Mass Index; CD40 Ligand; Chromans; Chronic Diseas | 2003 |
13 other studies available for troglitazone and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-gamma expression in splenic T cells.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Chromans; Cytokine | 2003 |
A retrospective review of thiazolidinediones with development of a troglitazone conversion protocol.
Topics: Aged; Alanine Transaminase; Chromans; Clinical Protocols; Contraindications; Diabetes Mellitus, Type | 2003 |
Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity.
Topics: Animals; Cell Survival; Cells, Cultured; Chromans; Diabetes Mellitus, Type 1; Fatty Acids, Nonesteri | 1997 |
Effect of troglitazone on blood insulin levels after pancreas transplantation with systemic venous drainage in rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Type 1; Drainage; Glucose Toleranc | 1997 |
Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 1; Diabetes M | 1998 |
Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.
Topics: Age Factors; Animals; Chromans; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 1; Fem | 1998 |
Troglitazone, a new antidiabetic agent, decreases cyclosporine level.
Topics: Aged; Chromans; Cyclosporine; Diabetes Mellitus, Type 1; Drug Interactions; Heart Transplantation; H | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran | 1998 |
Severe hepatotoxicity associated with troglitazone.
Topics: Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fatal Outcome; Female; Humans; Hypoglycemic Agents | 1999 |
Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.
Topics: Animals; Blood Glucose; Chromans; Cricetinae; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 1999 |
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Topics: Adult; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Diabetes Mellitus, Type 1; Fat | 2001 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria | 2001 |